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Opinion statement
Medication-overuse headache—i.e., a too-frequent consumption of acute headache med-
ications leading to increased headache frequency and reduced effectiveness of acute and
preventive treatments—is a serious medical condition whose pathophysiology still re-
mains incompletely known, which is reflected into a lack of mechanism-based treatments.
The first mandatory step in the therapeutic strategy remains withdrawal of the abused
drug, preferably abrupt, in concomitance with a detoxification pharmacological regimen
to lessen withdrawal symptoms. Intravenous hydration, antiemetics, corticosteroids
(prednisone), tranquilizers (benzodiazepine), neuroleptics, and rescue medication (an-
other analgesic than the overused) should be delivered in various combinations, on an
inpatient (hospitalization and day hospital) basis or outpatient basis, depending on the
characteristics of the specific patient and type of overuse. Inpatient withdrawal should be
preferred in barbiturate and opioid overuse, in concomitant depression, or, in general, in
patients who have difficulty in stopping the overused medication as outpatients. In
contrast, in overuse limited to simple analgesics in highly motivated patients, without
high levels of depression and/or anxiety, home detoxification should be chosen. Re-
prophylaxis should immediately follow detoxification, ideally with local injections of
onabotulinumtoxinA every 3 months or topiramate orally for at least 3 months. Adequate
information to patients about the risks of a too-frequent consumption of symptomatic
headache medications is essential and should constantly parallel treatment to help
preventing relapse after detoxification and re-prophylaxis.
Introduction
Headache is a very frequent medical condition and
among the top three causes of disability worldwide
[1–4]. Though most headaches are episodic, 2–5 %
of the general population experience chronic forms,
i.e., headache for ≥15 days per month. Medication-
overuse headache (MOH), i.e., a too-frequent con-
sumption of acute headache medications, develops
in approximately 50 % of the patients with chronic
headache, although virtually any patient with a pri-
mary episodic headache may be at risk of the condi-
tion [3–5, 6••, 7]. The estimated world prevalence of
MOH is 0.5–7.2 %; women are mainly affected
(M/F=1:4) with peak prevalence around 40 years
and a decline with age, prevalence reaching 1–
1.5 % among people over 65 years. MOH prevalence
is also inversely related to socioeconomic position
[6••, 8, 9].
Migraine is the most common diagnosis leading to
MOH due to overuse of specific antimigraine drugs
(triptans and ergot alkaloids] or non-specific drugs
[non-steroidal anti-inflammatory drugs (NSAIDs), aspirin,
simple analgesics, and combination analgesics], while
MOH developing in tension-type headache is most
often caused by NSAID overuse. The mean critical
duration of overuse would be shortest for triptans
(1.7 years), longer for ergotamine (2.7 years), and
longest for simple analgesics (4.8 years) [10–12]. In
Europe, MOH is rarely caused by overuse of opioids,
employment of these compounds for symptomatic
headache being largely discouraged in the medical
environment [13]. Although not recommended as
first-line therapy by consensus guidelines, in the
USA, opioid analgesics are instead commonly used to
treat headaches, and the related medication-overuse
represents a significant clinical problem, whose man-
agement is particularly complex and usually produces
poorer outcomes (see section on BTreatment^) [14].
Whatever the medication-overuse headache agent
(MOHA), a history of gradual increase in the usage
of the specific MOHA is often present, which is then
accompanied by increasing frequency of headache
with decreasing effectiveness of the individual doses
of MOHA in relieving the individual headaches. Re-
duced effectiveness of preventative treatments is also
a typical consequence of MOH [12]. Most often
comorbid with emotional and psychiatric distur-
bance, such as depression or anxiety, and numerous
additional pain and non-pain medical conditions,
MOH produces decreased quality of life and in-
creased disability [15–23].
BHeadache induced by chronic substance use or
exposure^ was already described in the 1988 Inter-
national Headache Society (IHS) Headache Classifi-
cation; the term MOH, however, only appeared in
the 2004 edition, where MOH was defined as prob-
able, until its improvement after detoxification/
withdrawal of medication allowed a definite diagno-
sis [6••, 24, 25]. The last HIS criteria published in
2013 define MOH as headache manifesting on
≥15 days/month in a patient with a preexisting head-
ache disorder, developing as a consequence of regu-
lar overuse of acute or symptomatic headache med-
ication (on ≥10 or ≥15 days/month, depending on
the medication) for more than 3 months, which
usually, but not constantly, resolves after interrup-
tion of the overuse (Table 1) [26, 27]. With these
criteria, MOH can be diagnosed immediately and
independently of withdrawal.
The pathophysiology of the condition is still partially
unknown. After medication overuse, an increased excit-
ability has been demonstrated of neurons in the cerebral
cortex, which may facilitate the occurrence of cortical
spreading depression, and trigeminal system, which
may promote phenomena of peripheral and central
sensitization. These changes are probably the result of
alterations in several modulating systems (e.g., seroto-
nin, endocannabinoid dependent) at the central level,
involved in pain perception in genetically predisposed
individuals [11, 28•].
There are currently no internationally accepted
guidelines for the treatment of MOH and protocol strat-
egies vary greatly among centers [5, 6••]. The most
frequent therapeutic steps are abrupt or gradual with-
drawal of the abused drug, an inpatient or outpatient
detoxification protocol regimen, and re-prophylaxis,
generally with onabotulinumtoxinA or topiramate, to
prevent relapse, whose risk is highest in the first
12 months [12].
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Treatment
General considerations for treatment protocols
Due to pathophysiological uncertainty, there is still a lack of mechanism-based
therapies and, as already stated in the BIntroduction^, specific guidelines for the
management of MOH are currently not available [5, 6••]. Regardless of the
strategy, however, the scientific community agrees that the main aims of the
treatment are as follows: (i) Withdrawal of the overused drug leading to
detoxification(s), (ii) pharmacological and non-pharmacological support pro-
vided to patients, and (iii) prevention of relapse.
In all patients, independently of the type of abuse, particular attention should
be paid to the presence of comorbidities, especially psychiatric, e.g., depression,
anxiety, and bipolar disorder, in regard to themodalities of withdrawal, and type
of support during detoxification and in the follow-up period [8, 21].
Withdrawal/detoxification and re-prophylaxis
Withdrawal of the overused drug/s is the first mandatory approach since
this inmost cases leads to an improvement of the headache.However, there
are still many debated areas with this respect, for instance, if withdrawal
should be abrupt or gradual, which protocol of support should be given to
patients during withdrawal, which is the preferred setting during detoxifi-
cation, i.e., inpatient versus outpatient care, or whether or not prophylactic
medication should be initiated immediately at withdrawal or after with-
drawal therapy has been completed.
Some studies seem to indicate that simple advice to withdrawal is effective. For
example, in patients affected with MOH for 8–18 years, a population-based
study carried out in Norway showed a notable improvement subsequent to
simple information about the use ofmedication: 42% of the patients reverted
to episodic headache and 76%were free of medication overuse after 1.5 years
[29]. This study, however, was observational and lacked a control group.
Table 1. Medication-overuse headache
Diagnostic criteria:
A. Headache occurring on ≥15 days per month in a patient with a preexisting headache disorder
B. Regular overuse for 93 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache
for ≥10 days/month, ergotamine, triptans, opioids, combination analgesics, multiple drug classes not
individually overused, unverified overuse of multiple drug classes, and one or more medications other than
those described above and below
for ≥15 days/month, simple analgesics: paracetamol or acetylsalicylic acid or other non-steroidal
anti-inflammatory drug (NSAID)(one or more NSAIDs other than acetylsalicylic acid)
C. Not better accounted for by another ICHD-3 diagnosis
ICHD-3 beta 2013
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Further studies by Italian neurologists also showed the efficacy of simple
advice in reverting MOH at 2 months in 78–92 % of patients with simple
MOH and 60 % of patients with complicated MOH [30, 31].
A recent paper by Munksgaard and Jensen [32•] reviewing the literature on
MOH treatment also suggests that simple detoxification and information
can reduce headache frequency to episodic headache in over 50 % of the
patients, with approximately half of the patients not needing prophylactic
treatment after withdrawal. Also, pain hypersensitivity, typically present in
MOH and indicating central sensitization, reverts in patients successfully
detoxified, indicating a reversible mechanism at the basis of the condition.
However, other authors report much less favorable outcomes with simple
withdrawal and advice and are thus in favor of a more robust support to
patients during detoxification. In this phase, in fact, the majority of the
patients present withdrawal symptoms for 2–10 days, i.e., rebound head-
ache (initial worsening of the headache), nausea, vomiting, hypotension,
tachycardia, restlessness, anxiety, nervousness, and sleep disturbances.
Withdrawal headaches have different duration, depending on the drugs
causing the overuse, i.e., it is shorter in patients overusing triptans
(4.1 days) than in those overusing ergotamine (6.7 days) or NSAIDs/
analgesics (9.5 days) [5, 6••]. Withdrawal from drugs containing barbitu-
rates and antimigraine compounds may also produce seizures or halluci-
nations. Various drug classes can be used to lessen/eliminate these symp-
toms, although detoxification drug protocols differ greatly among different
centers (see specific sections below). Different settings have been suggested
for successful withdrawal/detoxification: home treatment, hospitalization,
or day hospital. Inpatient withdrawal (2 days–2 weeks) seems the most
effective (reported success around 70 %) and it should be the preferred
approach in patients with barbiturate and opioid overuse, depressed pa-
tients, or, in general, patients who have difficulty in stopping the overused
medication as outpatients. In contrast, highly motivated patients, without
high levels of depression and/or anxiety, in whom the overuse is limited to
simple analgesics or analgesics not containing barbiturates or opioids better
benefit from an outpatient detoxification approach [13]. A day-hospital
regimen is also useful, with patients remaining in the hospital for no longer
than 6 h during pharmacological infusion treatment [12]. Abrupt versus
gradual suspension of the abused drug is another point of debate. There are
currently no studies directly comparing the results of abrupt versus gradual
suspension; however, the clinical experience suggests that in most cases,
abrupt interruption achieves better results as it probably promotes a fast
resolution of the drug-induced pain-coping behavior [33]. Abrupt discon-
tinuation can be performed with overuse of triptans, ergots, paracetamol,
aspirin, and NSAIDs, while barbiturates, opioids, and benzodiazepines,
unless replaced with long-acting derivatives, must be tapered to avoid a
serious withdrawal syndrome. A gradual reduction is also preferred with
compounds containing caffeine [13].
The role of re-prophylaxis is still controversial. Prophylactic treatment with
onabotulinumtoxinA and topiramate in chronic migraine with MOH (see
below) has proven effective in placebo-controlled studies, with a significant
reduction of headache days per month [34–37]. However, these results have
proven not superior to detoxificationwithout prophylactic treatment in some
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studies [29, 38]. On this basis, a number of authors believe that while initial
withdrawal is the treatment of choice in MOH, prophylaxis should be
restricted to patients who do not obtain sufficient results from withdrawal
[30]. Since it is still not possible to predict in advance the response/lack of
response to withdrawal in the single patient, however, other authors are in
favor of prophylaxis to be applied routinely in every case, to optimize the
outcome. Whether prophylaxis should be started immediately at withdrawal
or after completion of the withdrawal process remains debated [39•].
Follow-up, relapse, and long-term outcome
The follow-up of patients subjected to detoxification has shown controversial
results. The short-term response (2-month follow-up) to drug withdrawal in
MOH has been suggested to be genetically determined [40]. Regarding
relapse, recent studies indicate that the highest risk is in the first 12 months,
although different percentages are reported by various authors (22–44 % in
Trucco et al. [41]; 60–75 % in Zidverc et al. [42] and Baumgartner et al. [43];
or 40–60 % in Andrasik [15], Katsarava [44], Hagen et al. [45], and Fritsche
et al. [46]). The risk decreases, however, if medication overuse is avoided for
12 months after withdrawal, and in general, MOH treatment is considered
successful if the improvement obtained after withdrawal/detoxification with
or without prophylaxis is maintained at 1-year follow-up [42, 47–51].
Several factors are considered a risk for relapse: male sex, a diagnosis of
tension-type headache or mixed headache, frequency of the primary head-
ache, higher severity of the migraine condition, long duration of drug over-
use, greater number of previous prophylactic treatments, intake of combina-
tion analgesic products (e.g., one or more NSAIDs with caffeine or codeine)
or of codeine-containing drugs, ergotamine or triptan withdrawal more than
analgesic withdrawal, use of the same drug that has caused overuse, lower
improvement after drug withdrawal, reduced sleep quality, and high levels of
body pain and of disability score for chronic headache [12]. Psychiatric
comorbidity has also been suggested to be a predictor of reduced response to
treatment [13, 52]. Pharmacogenomics studies will hopefully allow the
medical community to be involved in headache treatment to better predict
the outcome of drug treatment and thus help in managing the condition.
The long-term prognosis in MOHhas been investigated in lesser detail with
respect to the short-term outcome. Prospective studies that included pa-
tients with triptan-induced MOH have reported relapse rates after success-
ful drug detoxification therapy of 38 % in the first year and 42 % after
4 years [44, 47]. Patients with tension-type headache had higher relapse
rates than migraine patients, and analgesic overusers had higher relapse
rates than ergot and triptan overusers [51]. Results on long-term relapse in
the literature should, however, be compared with some caution, since the
studies varied in the use of different headache classification systems, dif-
ferent withdrawal and prophylaxis, and follow-up and criteria for im-
provement. Furthermore, the percentages of relapse with the same MOHA
versus relapse with a different MOHA in the same patients still remain to be
precisely determined with appropriately designed investigation [5].
Prevention represents the most crucial aspect for MOH, and numerous
studies underline the key role played by information to the headache
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patients about the risk of the overuse of medications [53]. The major steps
in the treatment approach to MOH are summarized in Table 2.
Pharmacological treatment
Drug therapy is aimed at reducing withdrawal symptoms during the detoxifi-
cation phase, at preventing subsequent relapse (re-prophylaxis), and then at
stabilizing the residual headache (standard long-term treatment).
Detoxification/Rehabilitation
Pharmacological protocols for detoxification/rehabilitation are highly variable
in the various centers. The following are most frequently used in the majority of
the patients: intravenous hydration, corticosteroids, antiemetics, tranquilizers,
neuroleptics, and rescue medication (another analgesic than the overused).
Intravenous dihydroergotamine (DHE) is also used specifically in inpatient
protocols in the very first phases (4 days, every 8 h) of the detoxification
process, in combinationwith an antiemetic to control nausea, which is themost
frequent side effect. It has been shown to be efficacious, shortening hospital stay
and reducing analgesic withdrawal symptoms. Due to the temporarily effect of
blood vessel vasoconstrictions, DHE is, however, contraindicated in patients
with a past history of cardiovascular disease or stroke [13].
Regarding corticosteroids, oral prednisone represents the most common
treatment during detoxification [12]; when compared with placebo, it reduces
the duration of withdrawal headache [33, 54–56]. The use of prednisolone has
instead produced mixed results; in particular, it has been found to be not
superior to placebo in two placebo-controlled studies [57, 58].
As a general rule, steroids should be employed with particular caution in
patients with significant comorbidities, considering the long list of their con-
traindications. The risk of steroid psychosis furthermore needs to be taken into
account during acute treatment in the detoxification phase, with immediate
suspension of the drug, should any symptoms of the condition appear, e.g.,
hallucinations, combined to eventual therapy with phenothiazines [13].
Recently, a double-blind, parallel-group, clinical trial by Taghdiri et al. [59]
compared the efficacy of celecoxib (400 mg/day for the first 5 days and then
decreased at a rate of 100 mg every 5 days) versus prednisone, orally (75 mg/day
Table 2. Therapeutic steps in MOH
• Educate the patient on MOH and obtain assent for treatment
• Withdrawal or detoxification
• Treat the headaches associated with detoxification
• Use appropriate prophylactic antimigraine agents either early or later after detoxification
• Treat residual headache
• Provide appropriate psychiatric support when necessary
• Be prepared for longer term follow-up to help the patient from relapsing into MOH again
Source: Couch and Lenaerts, 2007
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for the first 5 days and then tapered off every 5 days) in MOH. In the celecoxib
group, headache intensity was lower than in the prednisone group during the first
3 weeks after withdrawal, although headache frequency and the need for rescue
medication intake were not different between the two groups. The authors con-
clude that the use of celecoxib and prednisone is equivalent toward the reduction
of headache days or rescue medication intake during withdrawal in MOH.
Whatever the main drug used in the detoxification protocol, antiemetics,
such as promethazine, hydroxyzine, or metoclopramide, should systematically
be delivered [5, 13].
A typical inpatient protocol adopted at eight Italian hospitals provided
satisfactory results at 6-month follow-up in patients with probable chronic
migraine and chronic MOH. It involved abrupt discontinuation of the overused
drug and therapywith i.v. hydration, steroids (dexamethasone, 4mg i.v./day for
1 week), and benzodiazepines (diazepam 6 mg/day for 10 days) along with
metoclopramide and early prophylaxis (initiated soon after hospital admis-
sion) [60].
Re-prophylaxis
Topiramate and local injection of onabotulinumtoxinA are the compounds
with the best evidence of efficacy as therapeutic agents for re-prophylaxis after
detoxification in patients with chronic migraine with and without overuse.
Topiramate has been proven effective in decreasing the number of migraine
days in multicenter, randomized, double-blind, placebo controlled trials [61–
63], and onabotulinumtoxinA has also significantly reduced headache pain in
MOH associated with chronic migraine [64].
The comparative efficacy and safety of these two approaches for chronic
migraine were evaluated in two studies [65, 66]. Both drugs proved equally
effective in improving several pain/disability parameters, but the safety profile
was higher for onabotulinumtoxinA and the discontinuation rate significantly
higher for topiramate [adverse events (AEs) being the major reason for with-
drawal] (discontinuation rates 25–44.2 % for topiramate; 10–25 % for
onabotulinumtoxinA) [12, 65–69].
These results indicate that onabotulinumtoxinA is an important option for
re-prophylaxis in chronic migraine associated with MOH.
Sodium valproate and amitriptyline have also been recently tested in re-
prophylaxis of MOH, althoughmore studies are needed with these compounds
to confirm the results [70•, 71].
The phase of re-prophylaxis is particularly critical, as it regards the immedi-
ate post-detoxification period, where the risk of relapse is highest. This phase
should preferentially be handled by the samemedical staff that has taken care of
detoxification, with the physician being ready to help in the case of relapse [72,
73].
Topiramate
& Topiramate acts through different mechanisms: inhibitory effects on
voltage-gated sodium and calcium channels, modulation of glutamate-
mediated neurotransmission, enhancement of some gamma-
aminobutyric acid (GABA) A receptors, and inhibition of carbonic
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anhydrase. It reduces excitatory neurotransmission and enhances in-
hibitory neurotransmission.
Dose 25mg/day orally for a week and then increase by 25mg/day every week till
100 mg/day (50 mg×2/day) to be maintained for 3 months 100 mg/day
orally for 3 months
Contraindications Depression, glaucoma, liver and kidney disease, hypokalemia, acidosis,
and pregnancy
Main interactions Alcohol, CNS depressant drugs, and contraceptives
Side effects/AE Paresthesias (8.0 %), cognitive symptoms (difficulty with concentration/
attention and memory) (7.3 %), fatigue (4.7 %), insomnia (3.4 %), nausea
(2.3 %), loss of appetite, anxiety, permanent reduction of visual acuity, and
dizziness (2.1 %)
Paresthesia, due to the inhibition of carbonic anhydrase, is the most common
side effect (which can be lessened by potassium supplementation, e.g., 48 mEq/
day) although it does not constitute themain reason for therapy discontinuation.
The majority of AEs appear during the titration period, generally within 6 weeks,
suggesting that in the case that patients do not present AEs by the end of such
period, they will by safe from such events [56, 60].
OnabotulinumtoxinA
& This neurotoxin blocks neuromuscular transmission by binding to
acceptor sites on motor or sympathetic nerve terminals, entering the
nerve terminals, and inhibiting the release of acetylcholine, a neuro-
transmitter at somatic neuromuscular junctions, at the parasympathetic
nervous system, at sympathetic preganglionic fibers (cholinergic fi-
bers), and at some synapses in the central nervous system. In addition
to the well-documented myorelaxant effects, onabotulinumtoxinA can
have a direct analgesic effect that likely involves inhibition of primary
and secondary nociceptive neurons [74].
Dose 155 units (1 ml/100 Units), subcutaneously or intramuscularly, divided
across 31 points, seven specific head and neck muscles (frontalis, corrugator,
procerus, occipitalis, temporalis, trapezius, and cervical paraspinal muscle
group) fixed sites fixed doses (FSFD) protocol, [all muscles injected bilater-
ally with the exception of the procerus muscle which should be injected at
one site (midline)] plus, eventually, BFollow The Pain (FTP) protocol^
(40 units/8 points), administered at intervals of at least 12 weeks [75].
Contraindications Infection at the proposed injection site(s) and hypersensitivity to any
botulinum toxin preparation or ingredient in the formulations
Main drug interactions Aminoglycosides (e.g., gentamicin), drugs interfering with neuromuscular
transmission (e.g., quinidine) (the effects of onabotulinumtoxinA may be
potentiated), anticholinergic agents (e.g., atropine) (systemic anticholin-
ergic effects, .e.g., blurred vision, may be potentiated), andmuscle relaxants
(excessive weakness)
Side effects/adverse events Neck pain (9 %), muscle weakness (5.5 %), and headache (5 %). Severe
worsening of migraine requiring hospitalization has been reported in
approximately 1 % of patients, usually occurring within the first week of
treatment (vs placebo, 0.3 %). Other effects include eyelid ptosis,
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musculoskeletal stiffness, myalgia, musculoskeletal pain and muscle
spasms, and injection site pain. No distant spread of toxin effect has been
reported at doses recommended for migraine prophylaxis [35, 36, 76].
Sodium valproate
Sodium valproate, the acid salt of valproic acid, has anticonvulsant effects mainly
due to the blockade of voltage-dependent sodium channels and increased brain
levels of GABA. A recent multicenter, randomized, double-blind, placebo-
controlled trial (SAMOHA) has investigated the effects of sodium valproate
versus placebo [the study randomized 88MOHpatients for a 3-month treatment
period with sodium valproate (VPA) (800 mg/day) or placebo after a 6-day
outpatient detoxification regimen] in the short-term treatment of MOH after
detoxification in patients with a history of migraine without aura, showing the
efficacy and safety of this therapeutic approach [70•]. The 3-month responder
rate (the proportion of patients achieving ≥50% reduction in the number of days
with headache per month) was, in fact, 23.8 % for the placebo arm and 45% for
the VPA arm; however, after a 3-month follow-up period, this rate did not differ
between the two groups. In a subsequent ancillary study, a further analysis of the
data from this trial, on both the placebo and active groups, furthermore showed
that in MOH patients with a history of migraine longer than 30 years, there was
no benefit from detoxification and advice to withdraw from drug abuse without
preventive therapy. This lack of benefit could be due to the lingering central
sensitization underlying the pathophysiology of MOH [39•].
Dose 800 mg/day orally for 3 months
Contraindications Preexisting liver and pancreatic disease/dysfunction and pregnancy
Main drug interactions Alcohol and benzodiazepines (CNS depressant effectsmay be potentiated),
other antiepileptics, anticoagulants, aspirin, erythromycin, carbapenem,
and cimetidine
Side effects/adverse events Digestive symptoms (diarrhea, nausea, and vomiting), vision problems,
hormonal disturbances (e.g., menstrual irregularities in women), weight
gain, memory problems, hair loss, dizziness, tremor, drowsiness, infec-
tions, and low platelet count. Less common but more serious: liver and
pancreatic damage, movement disorders, and psychiatric/neurological
disturbances (hallucinations, confusion, and anxiety)
Amitriptyline
Amitriptyline, a tricyclic antidepressant, acts primarily as a serotonin-
norepinephrine re-uptake inhibitor, with strong actions on the serotonin trans-
porter and moderate effects on the norepinephrine transporter.
An open-label design study by Fan et al. [71] evaluated the long-term
efficacy of low-dose amitriptyline in combination with abrupt withdrawal for
MOH in an outpatient setting for a 1-year observational period. Headache
frequency and drug consumption at 3 and 12 months were significantly re-
duced with respect to baseline, with 58 % of the patients considered as
responders at 12 months, i.e., with ≥50 % reduction in headache frequency
from baseline and being without medication overuse. The authors conclude
that early introduction of low-dose amitriptyline combined with abrupt with-
drawal could be considered as a choice for patients with MOH, particularly
indicated in the case of comorbidity with fibromyalgia.
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Dose 10 mg/day orally for 3 months
Contraindications Pregnancy, history of myocardial infarction and arrhythmias, ischemic
heart disease and congestive heart failure, severe liver disease, and con-
comitant use of monoamine oxidase inhibitors (MAO)
Main drug interactions MAO (potential risk of serotonin syndrome), fluoxetine, anticholinergic
agents (atropine), antipsychotics, analgesics, antithyroid medication and
thyroid hormones, cimetidine, and serotoninergic agents (SSRIs and
triptans due to the potential for serotonin syndrome)
Side effects Dizziness, weight gain, delirium and confusion, anxiety and agitation,
orthostatic hypotension, loss of libido, impotence, sleep disturbances, and
drowsiness
Standard long-term treatment
There is normally an underlying headache problem which will have led
to the increasing use of symptomatic headache therapy that resulted in
MOH [72, 73]. After successful detoxification, this underlying headache
is usually still present and must be appropriately managed. Thus, once
the immediate post-detoxification phase is over and re-prophylaxis has
successfully avoided relapse, a standard re-treatment of the residual
headache should be initiated. For treatment of the acute attack, a drug
different from the one previously causing the abuse should be preferred,
eventually associated with an antiemetic in the case of significant
nausea/vomiting in migraine patients. If criteria for prophylaxis are still
present, a standard preventative treatment should also be carried out—in
cycles of 3 months—according to international guidelines, i.e., for mi-
graine with beta-blockers or calcium channel blockers or antiepileptics/
antidepressants, depending on the profile of the patient and the specific
comorbidities and for tension-type headache with antidepressants or
benzodiazepines [77–79]. Although in the long run, patients are not
necessarily followed by the same medical staff that has dealt with the
detoxification process, a stable and longer term relationship with the
physician who handled the MOH therapy usually proves to be very
helpful for stabilizing the results [72, 73].
Interventional procedures
Neurostimulation is becoming increasingly employed in the treatment of
chronic pain [80]; occipital nerve stimulation (ONS), in particular, is
providing encouraging results in refractory chronic migraine [1]. ONS,
obtained through an implanted device, is a relatively safe technique
compared to other invasive procedures, such as hypothalamic deep brain
stimulation. The most frequent adverse events are lead migration, local
immediate or delayed infections, and battery depletion due to high
stimulation intensities needed to obtain an optimal nerve stimulation in
some patients. Patients also complain of unpleasant traction on the
connecting cables and sometimes do not tolerate the paresthesias in-
duced by the stimulation of the occipital nerves. ONS probably acts
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through a non-specific neuromodulatory effect on central pain control
systems. Recommendations by the European Headache Federation [81,
82] state that from a medical standpoint, the application of a
neurostimulator, either in a trial or on the basis of a CE mark treatment,
should be considered only once all alternative drug and behavioral
therapies as recommended by international guidelines have failed and
medication-overuse headache is excluded. However, whether to include or
exclude patients suffering from MOH is currently being debated and it is
possible that future guidelines will reconsider this option also for MOH
[4]. In the meanwhile, a recent trial has indeed evaluated the
neurostimulation in chronic refractory headache without excluding
MOH, finding positive results, thus suggesting that MOH could benefit
from this interventional option in selected cases. Further studies should
be conducted in the field to definitively assess this aspect.
Conclusions
A standardized therapeutic approach to medication-overuse headache is
lacking at the present time. The results of the current management
options, in terms of immediate success of detoxification, as well as of
prevention of relapse, are still unsatisfactory, and further studies inves-
tigating the pathophysiology of the condition, combined with clinical
trials to test specific medications/protocols, are required to hopefully
achieve an internationally agreed standard of care for the condition.
While waiting for treatment guidelines, the importance of prevention
should be stressed in every possible medical context—from general
practice to specialistic context/hospital settings—by adequately informing
headache patients about the risks related to overuse of symptomatic
medications for their attacks [12, 83].
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